Profile data is unavailable for this security.
About the company
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
- Revenue in EUR (TTM)193.73m
- Net income in EUR28.74m
- Incorporated1988
- Employees321.00
- LocationPharming Group NVDarwinweg 24LEIDEN 2333 CRNetherlandsNLD
- Phone+31 715247400
- Fax+31 715247445
- Websitehttps://www.pharming.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avantium NV | 11.15m | -29.84m | 162.97m | 213.00 | -- | 1.25 | -- | 14.62 | -0.8783 | -0.8783 | 0.3288 | 3.06 | 0.0945 | 1.81 | 0.5133 | 52,347.42 | -26.11 | -29.36 | -33.35 | -35.74 | 78.91 | 83.57 | -276.43 | -266.38 | 5.08 | -10.24 | 0.1809 | -- | 10.69 | 0.7993 | -6.95 | -- | 15.45 | -- |
| Mithra Pharmaceuticals SA | 21.88m | -93.23m | 230.11m | 248.00 | -- | 5.85 | -- | 10.52 | -2.11 | -2.11 | 0.4924 | 0.7142 | 0.0504 | 0.3323 | 0.8899 | 88,237.91 | -21.45 | -16.55 | -26.85 | -19.42 | 33.46 | 88.16 | -426.03 | -138.21 | 0.4207 | -7.01 | 0.859 | -- | 151.03 | 0.1774 | -26.92 | -- | 5.63 | -- |
| Hyloris Pharmaceuticals SA | 3.29m | -8.28m | 375.21m | 14.00 | -- | 5.71 | -- | 114.01 | -0.3162 | -0.3162 | 0.1259 | 2.35 | 0.0481 | -- | 1.60 | 238,478.30 | -12.09 | -- | -13.52 | -- | 96.17 | -- | -251.63 | -- | -- | -20.31 | 0.0011 | -- | 1,669.14 | -- | -62.06 | -- | -- | -- |
| BenevolentAI SA | -100.00bn | -100.00bn | 568.44m | -- | -- | 2.42 | -- | -- | -- | -- | -- | 1.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0476 | -- | -- | -- | -- | -- | -- | -- |
| Pharming Group N.V. | 194.60m | 28.87m | 781.96m | 321.00 | 29.40 | 4.12 | 16.65 | 4.02 | 0.0408 | 0.0408 | 0.2756 | 0.2916 | 0.5217 | 0.5799 | 6.63 | 606,220.30 | 7.74 | 2.73 | 8.79 | 3.87 | 91.68 | 87.36 | 14.84 | 4.39 | 4.68 | -- | 0.41 | -- | -6.27 | 62.49 | -57.62 | -- | 66.17 | -- |
| Fagron NV | 625.79m | 69.41m | 914.60m | 3.06k | 13.18 | 2.46 | 9.13 | 1.46 | 0.9508 | 0.9508 | 8.57 | 5.10 | 0.7136 | 3.50 | 10.55 | 204,438.40 | 7.95 | 7.30 | 9.93 | 9.98 | 42.18 | 44.05 | 11.14 | 10.41 | 1.23 | 14.06 | 0.5278 | 12.97 | 3.21 | 6.35 | 2.35 | -- | 7.01 | -- |
| Galapagos NV | 624.03m | 5.57m | 2.48bn | 1.36k | 90.01 | 0.9201 | 87.45 | 3.97 | 0.4178 | 0.4178 | 11.10 | 40.86 | 0.1211 | -- | 9.17 | 476,719.60 | 0.108 | -2.45 | 0.121 | -2.75 | 98.57 | -- | 0.8918 | -17.82 | 8.34 | -- | 0.0084 | -- | 1.57 | 28.86 | 59.67 | -- | 64.60 | -- |
Data as of Dec 05 2022. Currency figures normalised to Pharming Group NV's reporting currency: Euro EUR
7.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Acadian Asset Management LLCas of 01 Sep 2022 | 19.98m | 3.07% |
| BlackRock Fund Advisorsas of 03 Nov 2022 | 10.54m | 1.62% |
| Healthinvest Partners ABas of 30 Jun 2022 | 6.25m | 0.96% |
| Nordea Investment Management ABas of 30 Sep 2022 | 3.48m | 0.53% |
| Schroder Investment Management North America, Inc.as of 28 Feb 2021 | 2.96m | 0.45% |
| KBC Asset Management NVas of 30 Jun 2022 | 1.53m | 0.24% |
| BlackRock Advisors (UK) Ltd.as of 03 Nov 2022 | 1.13m | 0.17% |
| First Private Investment Management KAG mbHas of 29 Jul 2022 | 1.10m | 0.17% |
| Mandarine Gestion SAas of 29 Jul 2022 | 1.00m | 0.15% |
| NN Investment Partners Belgium SAas of 31 Dec 2021 | 950.00k | 0.15% |
More ▼
Data from 31 Mar 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
